Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.56 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MARS1 | P56192 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.47 |
| ▸ | GCGR | P47871 | 2/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.45 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.44 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3867352 | 0.81 | PTGS2 (0.64) | MALT1SMN1; SMN2PTGS2PTGS1 | |
| SCHEMBL8591725 | 0.81 | MALT1 (0.55) | MALT1SMN1; SMN2MARS1GCGRCYP1A2 | |
| SCHEMBL29819771 | 0.81 | SLC16A3 (0.61) | MALT1SMN1; SMN2MARS1SLC16A3SLC16A1 | |
| SCHEMBL18300791 | 0.81 | SLC16A3 (0.61) | MALT1SMN1; SMN2MARS1SLC16A3SLC16A1 | |
| SCHEMBL5149159 | 0.80 | PTGS2 (0.66) | MALT1PTGS2PTGS1SLC16A3SLC16A1 | |
| SCHEMBL15579544 | 0.79 | FAAH (0.53) | MALT1SMN1; SMN2MARS1MAPK8CYP1A2 | |
| SCHEMBL4957791 | 0.78 | FAAH (0.46) | NR1H2SMN1; SMN2PTGS2PTGS1 | |
| SCHEMBL3712001 | 0.78 | MALT1 (0.51) | MALT1SMN1; SMN2MARS1MAPK8CYP1A2 | |
| SCHEMBL18307410 | 0.77 | SLC16A3 (0.60) | MALT1SLC16A3SLC16A1MCTS1 | |
| SCHEMBL20488594 | 0.76 | SMN1; SMN2 (0.54) | MALT1SMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7244753-B2 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2007-07-17 | — | — | US | claimed |
| US-20040072883-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. | 2004-04-15 | — | — | US | claimed |
| EP-1542972-A4 | CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20070238735-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITRODMED, INC. (US) | 2007-10-11 | — | — | US | disclosed |
| US-7244753-B2 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1542972-A2 | CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040072883-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. | 2004-04-15 | — | — | US | disclosed |
| WO-2004010945-A2 | CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072883-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | PTGS2, PTGIS, PTGES2 | MALT1 3536/4885NR1H2 859/4885SMN1; SMN2 2470/4885 |
| US-20070238735-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | PTGS2, PTGIS, PTGS1 | MALT1 3692/4885NR1H2 643/4885SMN1; SMN2 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.